New antipsychotic medications: Strategies for evaluation and selected findings

Schizophrenia Research

Volumn 27, Issue 2-3, 1997, Pages 249-259

  Schooler, Nina R ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Antipsychotic medications; Clinical trial designs; Clozapine; Olanzapine; Risperidone; Sertindole

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; RISPERIDONE; SERTINDOLE;

AGRANULOCYTOSIS; CLINICAL TRIAL; CONFERENCE PAPER; DRUG DESIGN; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; NEGATIVE SYNDROME; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHRONIC DISEASE; CLINICAL TRIALS; CLOZAPINE; DRUG ADMINISTRATION SCHEDULE; DRUG APPROVAL; HUMANS; IMIDAZOLES; INDOLES; PIRENZEPINE; PLACEBOS; PSYCHOTIC DISORDERS; RECURRENCE; RESEARCH DESIGN; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0030776066     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(97)00089-3     Document Type: Conference Paper

References (45)

1. Alvir, J.M.J., Jeffrey, P.H., Lieberman, M.D., et al., 1993. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N. Engl. J. Med. 329, 162-167.
2. American College of Neuropsychopharmacology (ACNP), 1997. A Statement of Principles of Ethical Conduct for Neuropsychopharmacologic Research in Human Studies, pp. 215-228.
3. Beasley, C.M., Tollefson, G., Tran, P., et al., 1996. Olanzapine versus placebo and haloperidol. Neuropsychopharmacology 14, 111-123.
4. Berman, I., Merson, A., Rachov-Pavlov, J., et al., 1995. Risperidone in elderly schizophrenic patients. Am. J. Geriatr. Psychiatry 4, 173-179..
5. Bondolfi, G., Baumann, P., Dufour, H., 1996. Treatment-resistant schizophrenia: clinical experience with new antipsychotics. Eur. Neuropsychopharmacol. 6, 21-25.
6. Borison, R.L., Pathiraja, A.P., Diamond, B.I., Meibach, R.C., 1992. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol. Bull. 28, 213-218..
7. Breier, A., Buchanan, R.W., Kirkpatrick, B., et al., 1994. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am. J. Psychiatry 151, 20-26.
8. Carpenter, W.T., , Schooler, N.R., Kane, J.M., 1997. The rationale and ethics of medication-free research in schizophrenia. Arch. Gen. Psychiatry 54, 401-407.
9. Chengappa, K.N.R., Baker, R.W., Kreinbrook, S.B., et al., 1995. . Clozapine use in female geriatric patients with psychoses. J. Geriatr. Psychiatry Neurol. 8, 12-15.
10. Chouinard, G., Jones, B., Remington, G., et al., 1993. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenia patients. J. Clin. Psychopharmacol. 13, 25-29.
11. Davis, J.M., Janicak, P.G., 1996. Risperidone: a new, novel (and better?) antipsychotic. Psychiatric Ann. 26, 78-87.
12. Emsley, R.A., McCreadie, R., Lemmens, P., 1995. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. American Psychiatric Association 148th Annual Meeting, Miami, Florida, 20-25 May 1995. New Research Program and Abstracts, NR465.
13. Essock, S.M., Hargreaves, W.A., Covell, N.H., Goethe, J., 1996. Antipsychotics in research and clinical settings. Psychopharmacol. Bull. 32, 683-697..
14. Gilbert, P.L., Harris, M.J., McAdams, L.A., et al., 1995. Neuroleptic withdrawal in schizophrenic patients. Arch. Gen. Psychiatry 52, 173-188.
15. Goldberg, S.C., Schooler, N.R., Davidson, E.M., Kayce, M., 1966. Sex and race differences in response to drug treatment among schizophrenics. Psychopharmacologia 31, 9
16. Hogarty, G.E., Schooler, N.R., Ulrich, R., et al., 1979. Depot fluphenazine and social therapy in the aftercare of schizophrenic patients: relapse analyses of a two-year controlled trial. Arch. Gen. Psychiatry 36, 1283-1294..
17. Jeste, D.V., Caligari, M.P., Paulsen, J.S., et al., 1995. Risk of tardive dyskinesia in older patients. Arch. Gen. Psychiatry 52, 756-764..
18. Jeste, D.V., Eastham, J.H., Lacro, J.P., et al., 1996. Management of late-life psychosis. J. Clin. Psychiatry 57, 39-45..
19. Kane, J., Honingfeld, G., Singer, J., et al., 1988. Clozapine for the treatment-resistant schizophrenic. Arch. Gen. Psychiatry 45, 789-796.
20. Kane J., Borenstein M., 1997. The use of placebo controls in psychiatric research. In: Shamoo, A.E. (Ed.), Ethics in Neurobiological Research with Human Subjects. Gordon and Breach Science, The Netherlands, pp. 207-214.
21. Keshavan M.S., Schooler N.R., Haas G.L., Sweeney J., in press. Biological change in early psychosis. Br. J. Psychiatry.
22. Kurland, A.A., Hanlon, T.E., Taton, M.H., et al., 1961. The comparative effectiveness of six phenothiazine compounds, phenobarbitol and inert placebo in the treatment of acutely ill patients: global measures of severity of illness. J. Nerv. Ment. Dis. 133, 1-18..
23. Lasky, J.J., Klett, C.J., Caffey, E.M., et al., 1962. Drug treatment of schizophrenic patients: a comparative evaluation f chlorpromazine, chlorprothixine, fluphenazine, reserpine, thioridazine and trifluopromazine. Dis. Nervous System 23, 698-706..
24. Leff, J.P., Wing, J.K., 1971. Trial of maintenance therapy in schizophrenia. Br. Med. J. 3, 559-604..
25. Leysen, J.E., Janssen, P.M.F., Megens, A.A.H.P., Schotte, A., 1994. Risperidone: A novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J. Clin. Psychiatry 55, 5-12.
26. Madhusoodanan, S., Brenner, R., Araujo, L., Abaza, A., 1995. Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. J. Clin. Psychiatry 56, 514-518..
27. Marder, S.R., Van Putten, T., , Mintz, J., et al., 1987. Low and conventional dose maintenance therapy with fluphenazine deconate: Two year outcome. Arch. Gen. Psychiatry 44, 518-521.
28. Marder, S.R., Meibach, R.C., 1994. Risperidone in the treat-ment of schizophrenia. Am. J. Psychiatry 151, 825-835..
29. Meltzer, H.Y., Burnett, S., Bastani, B., Ramirez, L., 1990. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp. Community Psychiatry 41, 892-897.
30. National Institute of Mental Health-Psychopharmacology Service Center Collaborative Study Group (NIMH-PSCN), 1962. Phenothiazine treatment in acute schizophrenia. Arch. Gen. Psychiatry 10, 246-261.
31. National Institute of Mental Health Psychopharmacology Research Branch Collaborative Study Group (NIMHPRBCSG), 1967. Differences in clinical effects of three phenothiazines in 'acute' schizophrenia. Dis. Nerv. Sys. 28, 369-383.
32. Pandalai, S.P., Schooler, N.R., Manevitz, A. et al., in press. Restabilization after relapse in the Treatment Strategies in Schizophrenia (TSS) Study. Psychopharm. Bull.
33. Peto, R., 1978. . Clinical trial methodology. Biomedicine 28, 24-36.
34. Peuskens, J., Risperidone Study Group, 1995. Risperidone in the treatment of chronic schizophrenic patients: a multinational multi-center double-blind parallel-group study versus haloperidol. Br. J. Psychiatry 166, 712-726.
35. Robinson, D., Woerner, M.G., Pollack, S., Lerner, G., 1996. Subject selection biases in clinical trials: data from a multicenter schizophrenia treatment study. J. Clin. Psychopharmacol. 16, 170-176.
36. Saltz, B.L., Woerner, M.G., , Kane, J.M., et al., 1991. Prospective study of tardive dyskinesia incidence in the elderly. JAMA 266, 2402-2406..
37. Salzman, C., Vaccaro, B., , Lieff, J., et al., 1995. Clozapine in older patients with psychosis and behavioral disruption. Am. J. Geriatr. Psychiatry 3, 26-33.
38. Schooler, N.R., 1991. Maintenance medication for schizophrenia: strategies for dose reduction. Schizophr. Bull. 17, 311-323..
39. Schooler, N.R., Kane, J., Marder, S., et al., 1995, Efficacy of clozapine vs haloperidol in a long term clinical trial: Preliminary findings. Schizophr. Res. 15, 165
40. Schooler, N.R., Keith, S.J., Severe, J.B., et al., 1997. Relapse and rehospitalization during maintenance treatment of schizophrenia: the effects of dose reduction and family treatment. Arch. Gen. Psychiatry 54, 453-464.
41. Schooler, N.R., Baker, R.W., in press. Providing quality care in the context of clinical research. In: Pincus, H. (Ed.), Informed Consent: A Resource Manual for Investigators, American Psychiatric Press.
42. Smith, R.C., Chua, J.W., Lipetsker, B., Bhattacharyya, A., 1996. Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: an open prospective study. J. Clin. Psychiatry 54, 460-466.
43. Spohn, H.E., Fitzpatrick, T., 1980. . Informed consent and bias in samples of schizophrenic subjects at risk for drug withdrawal. J. Abnorm. Psychol. 89, 79-92.
44. van Kammen, D.P., McEvoy, J.P., Targum S.D. et al., 1996. A randomized, controlled dose-ranging trial of sertindole in patient with schizophrenia. Psychopharmacology 124, 168-175.
45. Zimbroff, D.L., Kane, J.M., Tamminga, C.A., et al., 1997. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am. J. Psychiatry 154, 782-791..